Three cases of nivolumab therapy-failed advanced melanoma successfully controlled by ipilimumab with intensity-modulated radiotherapy.

Abstract

Anti-programmed death 1 antibody monotherapy is a first-line and widely used immunotherapy for the treatment of advanced melanoma. However, its efficacy rate is lower in the Japanese population compared with the Caucasian population. Ipilimumab is another immune checkpoint inhibitor (ICI) that activates and increases T cells, which suppress the function of regulatory T cells. Previous reports have suggested that ipilimumab is useful for treating advanced melanoma, particularly in combination with radiation therapy. In this report, we described three cases of nivolumab-resistant melanoma successfully controlled by ipilimumab with intensity-modulated radiotherapy, which may enhance the therapeutic effects of the sequential administration of ICI.

• Authors: Ryo Amagai, Taku Fujimura, Yumi Kambayashi, Yota Sato, Kayo Tanita, Akira Hashimoto, Setsuya Aiba
• Journal: The Journal of dermatology (J Dermatol) Vol. 46 Issue 5 Pg. 449-452 (May 2019) ISSN: 1346-8138 [Electronic] England
• PMID: 30908705 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2019 Japanese Dermatological Association.

Chemical References

• Ipilimumab
• Nivolumab

Topics

• Adult
• Aged
• Chemoradiotherapy (methods)
• Female
• Humans
• Ipilimumab (therapeutic use)
• Lymphatic Metastasis (diagnostic imaging, pathology)
• Male
• Melanoma (diagnosis, pathology, therapy)
• Middle Aged
• Neoplasm Staging
• Nivolumab (therapeutic use)
• Radiotherapy, Intensity-Modulated
• Skin (diagnostic imaging, pathology)
• Skin Neoplasms (diagnosis, pathology, therapy)
• Tomography, X-Ray Computed
• Treatment Outcome